ORGANON

Here to help families of every kind grow

Continuing our focus on women's health, Organon is your partner in meeting the reproductive needs of every patient type.

ORGANON

We're here for you with a focus on fertility

Whether you prescribe our products separately or in combination, the Organon fertility portfolio is here to help you meet the needs of your patients.

Interaction of Organon Product Portfolio in controlled ovarian stimulation[1-3]

Elonva® Sustained Follicle Stimulant (SFS) | **Puregon®** Recombinant FSH | **Orgalutran®** GnRH antagonist



GnRH antagonist protocol

- Start with a daily dose of Puregon® on day 2 or 3 of the cycle
- Start with daily administration of Orgalutran® 5–6 days after starting follicle stimulation with Puregon®
- As soon as 3 follicles of 16-20 mm are detected, and plasma estradiol levels of about 300-400 picogram/mL for each follicle >18 mm, the same day or the following day follicle maturation should be initiated by a single dose of hCG



GnRH antagonists/corifollitropin alfa protocol

- Start with a single dose of Elonva® in the early follicular phase
- Start with daily administration of Orgalutran® 5–6 days after starting follicle stimulation with Elonva®
- Puregon® is given 7 days after stimulation
- As soon as 3 follicles ≥ 17 mm are detected, the same day or the following day, follicle maturation should be initiated by a single dose of hCG

Puregon® Selected Safety Information

Precautions Hypothyroidism; adrenocortical insufficiency; hyperprolactinemia; pituitary or hypothalamic tumours; ovarian hyperstimulation syndrome (OHSS); ovarian torsion; thromboembolic events both in association with and separate from OHSS are possible; increased risk of multiplets and adverse maternal and perinatal outcomes; traces of streptomycin or neomycin may cause hypersensitivity reactions.

Contraindications For males and females: Hypersensitivity to the active substance or any of the excipients. Tumours of the ovary, breast, uterus, testis, pituitary or hypothalamus. Primary gonadal failure. Additionally for females Pregnancy. Undiagnosed vaginal bleeding. Ovarian cysts or enlarged ovaries, not related to polycystic ovarian syndrome (PCOS). Malformations of the reproductive organs incompatible with pregnancy. Fibroid tumours of the uterus incompatible with pregnancy.

Adverse Effects Hypersensitivity reactions: (erythaema, urticaria, rash and pruritus observed uncommonly). Female: Headache, abdominal distension, abdominal pain, OHSS, pelvic pain, injection site reaction, ovarian torsion, thromboembolism, unwanted ovarian hyperstimulation and multiple pregnancies. Male: Headache, acne, rash, epididymal cyst, gynecomastia, injection site induration. Please refer to full Product Information for complete list of adverse reactions.

Full Prescribing Information is available on request.
Please review the Product Information before prescribing at https://bit.ly/3ObaqKj

Every type of family is precious.

Utilise Puregon® for a tailored treatment approach across protocols, dosing, and responder types to help meet the individual needs of your patients.[3-5]

- **Recombinant FSH (rFSH) for daily administration with adjustable dosing in a precise drug delivery device[3,4]**

Puregon®
recombinant FSH
follitropin beta

Every patient journey is personal.

Give your patients the convenience of one, prefilled dose with proven efficacy to help meet their reproductive needs and start their families.[1]

- **SFS for single administration with the pre-filled syringe at the start of the stimulation or the early follicular phase[1]**

elonva®
corifolitropina alfa

Choose what may be best for the needs of your patients.

Orgalutran® comes as a single, pre-filled syringe used to help your patients move forward on their family journey.[2]

- **GnRH antagonist for daily administration with the single, prefilled syringe[2]**

Orgalutran®
ganirelix

Elonva® Selected Safety Information

Precautions Ovarian Hyperstimulation Syndrome (OHSS); renal insufficiency; ectopic pregnancy; ovarian torsion; congenital malformations; ovarian and other reproductive system neoplasms; thromboembolic events both in association and separate from OHSS; increased risk of multiplets and adverse maternal or perinatal outcomes.

Contraindications Hypersensitivity to the active substance or to any of the excipients. Tumours of the ovary, breast, uterus, pituitary or hypothalamus. Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause. Primary ovarian failure. Ovarian cysts or enlarged ovaries. Fibroid tumours of the uterus incompatible with pregnancy. Malformations of the reproductive organs incompatible with pregnancy. Pregnancy. Risk factors of OHSS e.g A history of OHSS, a previous COS cycle that resulted in more than 30 follicles ≥ 11 mm measured by ultrasound examination, a basal antral follicle count > 20, Polycystic ovarian syndrome (PCOS).

Adverse Effects Common: OHSS; pelvic pain and discomfort; headache; nausea; fatigue and breast tenderness. Uncommon: Mood swings; dizziness; hot flush; abdominal distension; vomiting; diarrhoea; constipation; back pain; abortion spontaneous; ovarian torsion; adnexa uteri pain; premature ovulation; breast pain; injection site haematoma; injection site pain and irritability; alanine aminotransferase increased; aspartate aminotransferase increased; procedural pain.

Full Prescribing Information is available on request.
Please review the Product Information before prescribing at https://bit.ly/3L8ou5x

Contact Kuan Yee Seung: +6017-31104032 to learn more about partnering with Organon fertility.

References: 1. Elonva® CCDS, Organon & Co., Inc., Feb 2019. **2.** Orgalutran® CCDS, Organon & Co., Inc., July 2020. **3.** Puregon® CCDS, Organon & Co., Inc., June 2019. **4.** Puregon Pen® CCDS, Organon & Co., Inc., April 2020. **5.** Kettel LM, Scholl G, Bonaventura L, et al. Evaluation of a pen device for self-administration of recombinant human FSH in clomiphene citrate-resistant anovulatory women undergoing ovulation induction. Reprod Biomed Online. 2004;9(4):373–380.

Orgalutran® Selected Safety Information

Precautions Hypothyroidism; adrenocortical insufficiency; hyperprolactinemia; pituitary or hypothalamic tumours; ovarian hyperstimulation syndrome (OHSS); ovarian torsion; serious pulmonary conditions have been reported; thromboembolic events both in association with and separate from OHSS are possible; increased risk of multiplets and adverse maternal and perinatal outcomes; traces of streptomycin or neomycin may cause hypersensitivity reactions.

Contraindications Ovarian enlargement or cyst not due to polycystic ovarian disease; tumours of ovary, breast, uterus, testes, hypothalamus and pituitary gland; prior hypersensitivity to the active substance or any of the excipients; conditions where a pregnancy would be particularly hazardous; unexplained vaginal bleeding; pregnancy; absence of an effective response and primary testicular failure. Not for use in the elderly or in children.

Adverse Effects Hypersensitivity reactions: (erythaema, urticaria, rash and pruritus observed uncommonly). Female: Headache, abdominal distension, abdominal pain, OHSS, pelvic pain, injection site reaction, ovarian torsion, thromboembolism, unwanted ovarian hyperstimulation and multiple pregnancies. Male: Headache, acne, rash, epididymal cyst, gynecomastia, injection site induration. Please refer to full Product Information document for complete list of adverse reactions.

Full Prescribing Information is available on request.
Please review the Product Information before prescribing at https://bit.ly/3JVNMCw

Organon Malaysia Sdn. Bhd.
Mercu 2, Level 40, Office 39-W022, No 3 Jalan Bangsar, KL Eco City,
59200 Wilayah Persekutuan, Kuala Lumpur, Malaysia.
PIC Contact:
+6017-311 4032

ORGANON